Selank Reconstitution Calculator

No. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is registered as a pharmaceutical in the Russian Federation and completed Phase III clinical testing there as a selective anxiolytic, but it has no FDA or EMA approval and no completed Western registration trials. It reaches US consumers as an unlicensed dietary supplement or nasal spray; EU control laboratories have seized preparations containing Selank as unapproved research peptides. It is not a controlled substance, but importation into most Western jurisdictions is legally grey-to-prohibited.

Controlled clinical studies established its use in generalized anxiety disorder and neurasthenia: anxiolysis comparable to medazepam plus added antiasthenic and psychostimulant effects in 62 patients; anxiety-phobic and somatoform disorders: pronounced anxiolytic and mild nootropic effect in 60 patients versus phenazepam; adjustment disorder: significant symptom-score reduction in 30 patients over 2 weeks; and post-COVID asthenia with anxiety/depressive symptoms: improvement after a 30-day intranasal course in 64 patients. Preclinical studies also document antiviral activity against influenza A/H3N2 and H5N1, herpes simplex virus types 1 and 2, and interferon-alpha induction. Two proposed mechanisms: positive allosteric modulation of GABA-A receptor binding and inhibition of enkephalin-degrading enzymes (IC50 ≈ 15–20 µM), raising endogenous enkephalin levels (mechanistic).

Intranasal is the only route validated in human trials and delivers glyprolines to the CNS more efficiently than intraperitoneal, intragastric, or intravenous administration. Route also changes the receptor profile (animal): intranasal Selank increased hippocampal NMDA binding with no GABA-receptor change, while intraperitoneal Selank increased cortical GABA-A binding sites, consistent with a more nootropic intranasal profile and a more anxiolytic systemic profile. Injectable use is community-driven only; lyophilized powder for injection is sold online without clinical validation (community protocol).

Human trial protocol: intranasal, 2–3 drops four times daily of the 1.5 mg nasal-drop formulation for 30 days; shorter 2-week courses are used for adjustment disorder. Community protocols: 100–300 µg per dose, 1–2 times daily, intranasal or subcutaneous, in 2–4-week cycles with breaks (community protocol). Animal dose-response: 100–300 µg/kg for anxiolytic/antidepressant effects; 1000–2000 µg/kg required in a genetic depression model.

Trial evidence supports a days-to-weeks trajectory: significant symptom reduction by 2 weeks in adjustment disorder, and earlier onset of phenazepam's therapeutic effect when Selank was added. Unlike benzodiazepines, the anxiolytic effect persisted for a week after the final dose, indicating neuroadaptive rather than acute receptor occupancy. Users frequently report felt effects within 10–30 minutes of nasal administration (community report), but this is not formally documented.

Human trials report no sedation, muscle relaxation, or cognitive impairment, and adding Selank to phenazepam reduced that drug's side effects (attention, memory, sedation, sleep disturbance). In mice, Selank enhanced diazepam's anxiolysis while blocking its sedative and motor-suppressant effects. In-vitro stem-cell assays found no toxicity toward embryonic cells, but there are no human pregnancy or lactation data; avoid use in pregnancy and breastfeeding until data emerge (practitioner consensus).

Head-to-head trials show anxiolytic efficacy comparable to phenazepam and medazepam, without benzodiazepine-type side effects and with no dependence signal documented. Selank does not occupy the benzodiazepine binding site; it modulates GABA binding allosterically and can interfere with diazepam/olanzapine modulation (in-vitro). Animal data show it potentiates benzodiazepine anxiolysis while counteracting sedation, supporting its use as a benzo-sparing adjunct or transitional agent.

No stability data exist in the published literature. Community practice: store lyophilized powder frozen (−20°C), refrigerate reconstituted solution (2–8°C) and use within 2–4 weeks, and refrigerate prepared nasal sprays (community protocol). Travel risk is real: Selank is an unlicensed medicine in the EU/US and shipments have been seized by customs laboratories; carrying it across borders risks confiscation even though the peptide itself is not scheduled (practitioner consensus).